/David Rosenthal

About David Rosenthal

This author has not yet filled in any details.
So far David Rosenthal has created 2 blog entries.

CURE and BioHaven Present Achillion: Transforming Innovation into Novel Therapies to Address Patient Needs

Presenting: Dr. Milind Deshpande Based in New Haven, Connecticut since 2001, Achillion Pharmaceuticals devotes their efforts to small molecule therapies. On behalf of the company, President and CEO Dr. Milind Deshpande discussed the recent particle development victories. Tracing back his journey as a scientist in the pharmaceutical industry, a good 20 years ago, he mentioned that the only thing known about the complement immune system was that “it existed”. Today, with the advancement in knowledge and science in general, we know about the many pathways involved in this system and the numerous proteins associated with it. Achillion’s remedies largely target [...]

By |July 8th, 2015|BioHaven, Blog|0 Comments

Bioscience ClubhouseCT Presents: A University-Public Company Joint Venture Success Story

On Tuesday, June 9th, the Founder, CEO, and Executive Chairman of Novogen, Dr. Graham Kelly, spoke on behalf of his company’s success. Novogen is an US-Australian public drug discovery company that has recently teamed with the Yale School of Medicine. Together, they call themselves CanTx. To date, cancer research companies strive to develop chemotherapies that target the body of a tumor. The body consists of rapidly diving daughter cells. These cells are derived from slow-dividing tumor-initiating stem cells, which are resistant to chemo- and radiotherapies. CanTx’s mission goes beyond today’s most efficient chemotherapy techniques and targets the cancer stem cells. [...]